394 Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 results

• Ignacio Melero,
• Diwakar Davar,
• Emiliano Calvo,
• Donald Richards,
• Sarina Piha-Paul,
• Matthew Dallos,
• Martin Gutierrez,
• Matteo Simonelli,
• Jason Melear,
• Janaki Parameswaran,
• Vinit Kumar,
• Xiaochen Zhao,
• Santanu Dutta

Affiliations

Ignacio Melero

9Universidad de Navarra, Pamplona, Spain

Diwakar Davar

1University of Pittsburgh Medical Center, Pittsburgh, PA, USA

Emiliano Calvo

4START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain

Donald Richards

5Texas Oncology, US Oncology Research, Austin, TX, USA

Sarina Piha-Paul

1MD Anderson Cancer Center, Houston, TX, USA

Matthew Dallos

7Columbia University Medical Center, New York, NY, USA

Martin Gutierrez

3Hackensack University Medical Center, Hackensack, NJ, USA

Matteo Simonelli

2Humanitas University; Humanitas Cancer Center – Humanitas Research Hospital, Milan, Italy

Jason Melear

5Texas Oncology, US Oncology Research, Austin, TX, USA

Janaki Parameswaran

8Bristol Myers Squibb, Princeton, NJ, USA

Vinit Kumar

8Bristol Myers Squibb, Princeton, NJ, USA

Xiaochen Zhao

Medical Affairs, 3D Medicines Inc, Shanghai, China

Santanu Dutta

8Bristol Myers Squibb, Princeton, NJ, USA